Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.

Provided is a mutant having an ability to overproduce carotenoids and a method for producing carotenoids by using the mutant. The mutant, of which mutations are induced by irradiation after being transformed with a recombinant vector according to the subject matter, has an excellent ability to produce carotenoids and can be mass-produced, and thus can be useful in various industrial fields, which use carotenoids, such as cosmetics, food, and feed.

The present disclosure describes the engineering of microbial cells for fermentative production of (6E)-8-hydroxygeraniol and provides novel engineered microbial cells and cultures, as well as related (6E)-8-hydroxygeraniol production method.

The present invention relates a variant polypeptide having geranylgeranyl pyrophosphate synthase activity, which variant polypeptide comprises an amino acid sequence which, when aligned with a geranylgeranyl pyrophosphate synthase comprising the sequence set out in SEQ ID NO: 1, comprises at least one substitution of an amino acid residue corresponding to any of amino acids at positions 92, 100 or 235 said positions being defined with reference to SEQ ID NO: 1 and wherein the variant has one or more modified properties as compared with a reference polypeptide having geranylgeranyl pyrophosphate synthase activity. A variant polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.

This invention relates to the field of genetic engineering. Specifically, the invention relates to the construction of operons to produce biologically active agents. For example, operons may be constructed to produce agents that control the function of biochemical pathway proteins (e.g., protein phosphatases, kinases and/or proteases). Such agents may include inhibitors and modulators that may be used in studying or controlling phosphatase function associated with abnormalities in a phosphatase pathway or expression level. Fusion proteins, such as light activated protein phosphatases, may be genetically encoded and expressed as photoswitchable phosphatases. Systems are provided for use in controlling phosphatase function within living cells or in identifying small molecule inhibitors/activator/modulator molecules of protein phosphatases associated with cell signaling.

The present invention relates to compositions and methods of producing carotenoids and carotenoid derivatives.

The invention relates to recombinant microorganisms and methods of producing citronellal, citronellol, citronellic acid, and/or citronellal/citronellol pathway intermediates and precursors.

This invention relates to the field of genetic engineering. Specifically, the invention relates to the construction of operons to produce biologically active agents. For example, operons may be constructed to produce agents that control the function of biochemical pathway proteins (e.g., protein phosphatases, kinases and/or proteases). Such agents may include inhibitors and modulators that may be used in studying or controlling phosphatase function associated with abnormalities in a phosphatase pathway or expression level. Fusion proteins, such as light activated protein phosphatases, may be genetically encoded and expressed as photoswitchable phosphatases. Systems are provided for use in controlling phosphatase function within living cells or in identifying small molecule inhibitors/activator/modulator molecules of protein phosphatases associated with cell signaling.

Disclosed herein are novel CBGA and CBGVA synthases and methods for improvement of their overall activities for the synthesis of CBGA and CBGVA from their respective precursors, olivetolic acid (OA) or divarinic acid (DVA) and GPP. Also disclosed are fusion proteins to enhance synthesis of CBGA and CBGVA. The methods described herein also increase the titer and the purity of CBGA and CBGVA made by a cell by 1) decreasing the formation of byproducts FCBGA and FCBGVA that are synthesized from the respective prenylation of OA and DVA with FPP, and/or 2) increasing the intracellular availability of OA and DVA.

A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.